Premium
Quality of Life and Sleep Outcomes in Obstructive Sleep Apnoea Following Transoral Robotic Surgery: A Meta‐Analysis
Author(s) -
Gupta Keshav Kumar,
De Mriganka,
Athanasiou Thanos,
Georgalas Christos,
Garas George
Publication year - 2025
Publication title -
clinical otolaryngology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.914
H-Index - 68
eISSN - 1749-4486
pISSN - 1749-4478
DOI - 10.1111/coa.14311
ABSTRACT Objective Obstructive sleep apnoea (OSA) can have a significant health burden in terms of sleep outcomes, systemic morbidity including cardiovascular and urological complications, and quality of life (QoL). Transoral robotic surgery (TORS) constitutes a novel option for patients where continuous positive airway pressure (CPAP) is not tolerated. This study aimed to assess OSA patients managed with TORS in terms of QoL and sleep outcomes. Data Sources Systematic review using EMBASE, CINAHL, MEDLINE, and Cochrane electronic databases. Review Methods Studies were identified assessing QoL (with validated QoL tools) and sleep outcomes in OSA patients managed with TORS. For the meta‐analysis, mean difference (MD) was calculated using an inverse variance random‐effects model. Results Four studies (252 patients) were included. Meta‐analysis showed improvements in apnoea‐hypopnea index (AHI) (MD = 20.01, p < 0.00001), Epworth Sleepiness Scale (ESS) (MD = 5.16, p < 0.00001) and lowest oxygen saturations (LSaO 2 ) (MD = ‐7.05, p < 0.00001) following TORS. For QoL, there were improvements in voice, prostate and overactive bladder symptoms, erectile function, and overall QoL following TORS. Swallowing returned to baseline at 3 months. No major complications were reported, with all adverse events managed conservatively. Conclusion This systematic review and meta‐analysis is the first in the existing literature to evaluate TORS as a treatment option for OSA across both sleep and QoL domains. Significant improvements were observed in both parameters following TORS. Whilst further research is needed, the current findings can assist clinicians and patients when it comes to clinical decision‐making regarding personalised treatment options for a condition that carries a significant morbidity and QoL burden. Trial Registration: PROSPERO: CRD42024448926
Empowering knowledge with every search
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom